Camlin Fine Sciences Ltd
Camlin Fine Sciences Ltd (CAMLINFINE) last reported results for the quarter ended Jun 2026, with sales of ₹520 crore and net profit of ₹-34 crore. The next scheduled event is a corporate event on 16 Oct 2026. The stock last traded at ₹93, a market capitalisation of ₹1,786 crore. Over the past 52 weeks the stock has ranged between ₹89.1 and ₹212. Figures are as of 6 Oct 2026 and are not real time.
Camlin Fine Sciences Ltd share price and key metrics
- Current price
- ₹93
- Market cap
- ₹1,786 cr
- Book value
- ₹54.2
- ROE
- 3.75%
- ROCE
- 4.78%
- Dividend yield
- 0.00%
- 52w high / low
- 212/89.1
Metrics as of 6 Oct 2026. Not real time.
Track Camlin Fine Sciences Ltd
Cruxal reads every Camlin Fine Sciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Camlin Fine Sciences Ltd growth and returns
- 10 Years
- 13%
- 5 Years
- 8%
- 3 Years
- 1%
- TTM
- 9%
- 10 Years
- -1%
- 5 Years
- -6%
- 3 Years
- -14%
- TTM
- -139%
- 10 Years
- 1%
- 5 Years
- -14%
- 3 Years
- -17%
- 1 Year
- -54%
- 10 Years
- -1%
- 5 Years
- -2%
- 3 Years
- -7%
- Last Year
- 4%
Camlin Fine Sciences Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹520 cr, up 27.5% from ₹408 cr a year earlier. Net profit was ₹-34 cr, down 209.1% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 417 | 431 | 432 | 408 | 460 | 441 | 425 | 520 |
| Expenses | 366 | 375 | 370 | 387 | 427 | 420 | 404 | 511 |
| Operating profit | 52 | 56 | 62 | 20 | 33 | 21 | 21 | 9 |
| OPM % | 12% | 13% | 14% | 5.0% | 7% | 4.7% | 5.0% | 1.8% |
| Other income | -151 | -8 | -22 | -0 | -4 | -24 | 103 | -10 |
| Interest | 26 | 34 | 15 | 15 | 19 | 17 | 23 | 14 |
| Depreciation | 17 | 14 | 17 | 16 | 19 | 16 | 21 | 19 |
| Profit before tax | -142 | -0 | 8 | -11 | -9 | -37 | 80 | -34 |
| Tax % | -18% | 2,164% | 98% | -0% | 65% | -0% | -8% | -1% |
| Net profit | -116 | -7 | 0 | -11 | -15 | -37 | 86 | -34 |
| EPS (₹) | -5.33 | -0.22 | -0.04 | -0.53 | -0.76 | -1.89 | 4.59 | -1.65 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Camlin Fine Sciences Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 534 | 721 | 892 | 1,049 | 1,187 | 1,412 | 1,682 | 1,454 | 1,629 | 1,723 | 1,845 |
| Operating profit | 32 | 16 | 73 | 135 | 187 | 158 | 211 | 170 | 227 | 118 | 84 |
| OPM % | 6% | 2.2% | 8% | 13% | 16% | 11% | 13% | 12% | 14% | 7% | 4.6% |
| Net profit | -4 | -24 | 3 | 30 | 65 | 60 | 40 | -105 | -158 | 24 | 1 |
| EPS (₹) | -0.96 | -2.18 | 0.04 | 2.23 | 3.56 | 3.45 | 2.96 | -4.94 | -7.40 | 1.44 | 0.29 |
TTM is the trailing twelve months to the most recent quarter.
Camlin Fine Sciences Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 10 | 12 | 12 | 12 | 13 | 16 | 16 | 17 | 19 | 19 |
| Reserves | 202 | 359 | 359 | 391 | 631 | 732 | 804 | 848 | 883 | 1,022 |
| Borrowings | 331 | 373 | 461 | 539 | 550 | 646 | 801 | 683 | 652 | 720 |
| Other liabilities | 126 | 273 | 255 | 290 | 282 | 396 | 425 | 424 | 467 | 559 |
| Total liabilities | 669 | 1,016 | 1,087 | 1,232 | 1,475 | 1,790 | 2,045 | 1,972 | 2,020 | 2,320 |
| Fixed assets | 201 | 278 | 272 | 306 | 584 | 601 | 858 | 816 | 704 | 887 |
| CWIP | 8 | 14 | 59 | 179 | 24 | 215 | 43 | 46 | 10 | 33 |
| Investments | 19 | 115 | 11 | 7 | 7 | 7 | 8 | 8 | 61 | 30 |
| Other assets | 442 | 609 | 745 | 740 | 861 | 966 | 1,136 | 1,102 | 1,246 | 1,370 |
| Total assets | 669 | 1,016 | 1,087 | 1,232 | 1,475 | 1,790 | 2,045 | 1,972 | 2,020 | 2,320 |
As reported by the company. Total assets equal total liabilities by construction.
Camlin Fine Sciences Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -9 | -15 | -9 | 86 | 117 | 145 | 51 | 139 | 23 | 82 |
| Cash from investing | -70 | -149 | -2 | -90 | -133 | -249 | -125 | -66 | -75 | -53 |
| Cash from financing | 91 | 182 | 26 | 3 | 39 | 136 | 60 | -86 | 76 | -25 |
| Net cash flow | 13 | 18 | 15 | -1 | 23 | 32 | -14 | -13 | 24 | 4 |
| Free cash flow | -39 | -34 | -78 | -48 | 34 | -68 | -93 | 79 | -19 | 20 |
| CFO / operating profit | 5% | -33% | 10% | 77% | 82% | 111% | 34% | 110% | 27% | 90% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Camlin Fine Sciences Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 5% | 0% | 7% | 11% | 13% | 10% | 10% | 8% | 12% | 5% |
| Debtor days | 99 | 104 | 86 | 88 | 83 | 77 | 66 | 72 | 74 | 79 |
| Inventory days | 277 | 207 | 219 | 204 | 200 | 178 | 255 | 256 | 234 | 199 |
| Days payable | 110 | 154 | 127 | 119 | 99 | 112 | 129 | 154 | 180 | 200 |
| Cash conversion cycle | 266 | 157 | 178 | 173 | 184 | 143 | 192 | 174 | 127 | 78 |
| Working capital days | -6 | 19 | 43 | 22 | 55 | 40 | 42 | 51 | 33 | 23 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Camlin Fine Sciences Ltd shareholding pattern
Promoters held 48.03% at Jun 2026, down from 49.09% at Jun 2025. FIIs 0.91% and DIIs 5.42%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 48.03% | 48.03% | 49.09% | 49.09% | 49.08% | 48.03% | 48.03% | 48.03% |
| FIIs | 0.81% | 0.76% | 1.47% | 2.88% | 2.11% | 2.12% | 0.94% | 0.91% |
| DIIs | 4.23% | 3.38% | 3.83% | 4.14% | 5.48% | 7.77% | 7.70% | 5.42% |
| Public | 46.93% | 47.83% | 45.61% | 43.88% | 43.33% | 42.07% | 43.31% | 45.63% |
| No. of shareholders | 67,750 | 61,893 | 58,111 | 59,538 | 57,661 | 52,357 | 52,232 | 55,178 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Camlin Fine Sciences Ltd events
The next scheduled event is a corporate event on 16 Oct 2026.
- Corporate eventPostal ballot for appointment of Mr. Atul Pradhan as a Non-Executive Independent Director
- EGMPostal ballot for special resolution
See the full results calendar for every Indian company reporting in the next 30 days.
Camlin Fine Sciences Ltd corporate filings
- Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2026.Company Updatelow impact
- Closure of trading windowInsider Trading / SASTlow impact
- Camlin Fine Sciences Ltd announces dispatch of Postal Ballot noticeCompany Updatelow impact
Cruxal's analysis: Camlin Fine Sciences Ltd has completed the dispatch of the notice for a Postal Ballot to…
Read the full analysis - Camlin Fine Sciences Limited Announces Postal Ballot for Appointment of Independent DirectorAGM/EGMlow impact
Cruxal's analysis: Camlin Fine Sciences Limited has issued a Postal Ballot Notice to seek shareholder…
Read the full analysis - Camlin Fine Sciences Limited appoints Mr. Atul Pradhan as Additional Non-Executive Independent DirectorCompany Updatelow impact
Cruxal's analysis: Camlin Fine Sciences Limited has announced the appointment of Mr. Atul Pradhan as an…
Read the full analysis - Camlin Fine Sciences Q1 FY27 Earnings Call: Margin Compression Due to Geopolitical Factors and Raw Material CostsCompany Updatehigh impact
Cruxal's analysis: Camlin Fine Sciences reported Q1 FY27 revenue of INR519.9 crore, reflecting a 28% YoY…
Read the full analysis - Camlin Fine Sciences Reports Q1 FY2027 Financial Results with Continued Net LossesCompany Updatehigh impact
Cruxal's analysis: Camlin Fine Sciences Limited reported its financial results for the quarter ended June…
Read the full analysis - Camlin Fine Sciences Ltd releases Q1 FY27 investor call recordingCompany Updatelow impact
Cruxal's analysis: Camlin Fine Sciences Ltd has filed the audio recording of its Q1 FY27 investor conference…
Read the full analysis - Camlin Fine Sciences Reports Q1 FY27 Financials: Record Revenue Growth Offset by Margin Pressure and Exceptional LossesCompany Updatehigh impact
Cruxal's analysis: Camlin Fine Sciences Limited reported Q1 FY27 revenue of 519.8 crore, a 27.5% YoY…
Read the full analysis - Camlin Fine Sciences Reports Consolidated Net Loss of 33.62 crore for Q1 FY27 Amidst Operational ChallengesResulthigh impact
Cruxal's analysis: Camlin Fine Sciences Limited reported a consolidated net loss of 33.62 crore for the…
Read the full analysis - Camlin Fine Sciences Limited concludes 33rd Annual General Meeting with all resolutions passedAGM/EGMlow impact
Cruxal's analysis: Camlin Fine Sciences Limited has successfully concluded its 33rd Annual General Meeting…
Read the full analysis - Camlin Fine Sciences to Host Q1 FY27 Earnings Call on August 11, 2026Company Updatelow impact
Cruxal's analysis: Camlin Fine Sciences Limited announced it will host a conference call with various…
Read the full analysis - Camlin Fine Sciences to Convene Board Meeting on August 11, 2026, for Q1 FY27 Financial Results ApprovalBoard Meetinglow impact
Cruxal's analysis: Camlin Fine Sciences Limited announced a board meeting scheduled for August 11, 2026, to…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.